Asian Journal of Andrology (Jan 2018)

PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China

  • Kai-Jie Wu,
  • Xin-Qi Pei,
  • Ge Tian,
  • Da-Peng Wu,
  • Jin-Hai Fan,
  • Yu-Mei Jiang,
  • Da-Lin He

DOI
https://doi.org/10.4103/aja.aja_34_17
Journal volume & issue
Vol. 20, no. 2
pp. 173 – 177

Abstract

Read online

Docetaxel-based chemotherapy remains the first-line treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) in China; however, the prognostic factors associated with effects in these patients are still controversial. In this study, we retrospectively reviewed the data from 71 eligible Chinese patients who received docetaxel chemotherapy from 2009 to 2016 in our hospital and experienced a reduction of prostate-specific antigen (PSA) level ≥50% during the treatment and investigated the potential role of time to nadir (TTN) of PSA. TTN was defined as the time from start of chemotherapy to the nadir of PSA level during the treatment. Multivariable Cox regression models and Kaplan-Meier analysis were used to predict overall survival (OS). In these patients, the median of TTN was 17 weeks. Patients with TTN ≥17 weeks had a longer response time to chemotherapy compared to TTN 50% PSA remission.

Keywords